



University of Wisconsin
MEDICAL SCHOOL

CME AND FACULTY INFORMATION

CME INFORMATION

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Wisconsin Medical School and MDG/HBV Watch®.

The University of Wisconsin Medical School designates this continuing medical education activity for a maximum of 0.75 category I credit towards the AMA Physician's Recognition Award. Each physician should claim only those hours that he/she actually spent in the educational activity.

To receive the 0.75 category I credit of CME credit, you must complete the CME Web Activity Evaluation Form and mail or fax it to:

University of Wisconsin Medical School CME
2701 International Lane #208
Madison, WI 53704
FAX: 608-240-2151

We are grateful for the independent educational grant provided by Bristol-Myers Squibb Company in support of this educational activity.

FACULTY INFORMATION AND DISCLOSURE

Douglas Richman, MD, is Professor of Pathology and Medicine (Infectious Diseases) at the University of California San Diego (UCSD) School of Medicine, San Diego, California, where he holds the Florence Seeley Riford Chair in Acquired Immune Deficiency Syndrome (AIDS) Research. He is also Director of the UCSD AIDS Research Institute and Director of the Research Center for AIDS and HIV Infection at the Veterans Administration San Diego Healthcare System. Before joining the UCSD faculty, Dr. Richman trained as an infectious diseases physician and medical virologist at Stanford University in Stanford, California, as well as at the National Institutes of Health (NIH) in Bethesda, Maryland, and at Harvard University in Boston, Massachusetts.

For more than 20 years, Dr. Richman's research has focused on human immunodeficiency virus (HIV) disease; his laboratory at UCSD was the first to identify HIV drug resistance. His research publications include more than 500 articles, reviews, and book chapters. He is the senior editor of *Clinical Virology*, a major textbook on medical virology. Dr. Richman is an invited lecturer and consultant both nationally and internationally. Among numerous awards, he has received an NIH MERIT Award and the Howard M. Temin Award for Clinical Science and Clinical Excellence in the Fight against HIV/AIDS. Dr. Richman has organized and chaired several important international meetings, including the HIV Drug Resistance Meeting and the Conference on Retroviruses and Opportunistic Infections.

Dr. Richman will discuss commercially available products during his lecture. His presentation will also reference unlabeled/unapproved uses of drugs or products.

Dr. Richman has acted as a consultant to Achillion, Anadys, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmith Kline, Idenix, Merck, Monogram, Pfizer and Roche.

CME WEB ACTIVITY
Management of Hepatitis B in HIV Coinfected Patients

1. Please evaluate this educational activity as a whole by filling in the appropriate circle:

| | Excellent | Very Good | Good | Fair | Poor |
|---------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|
| USEFULNESS | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> |
| QUALITY | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> |
| AUDIO-VISUALS | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> |
| EASY TO USE | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> |

2. Learning Objectives

Were the following learning objectives met?

- Describe the impact of coinfection with HIV on patients with HBV Yes No
- Among patients coinfecting with HIV and HBV, identify appropriate candidates for anti-HBV antiviral therapy Yes No
- Explain the optimal therapeutic approach for management of coinfecting patients who require therapy for HBV and for patients who require therapy for both HBV and HIV Yes No

If no, please state reasons:

3. General Comments

A. Do you feel that the program was fair, balanced, and free of commercial bias? Yes No

If no, please state reasons:

B. Suggested topics and/or authors/presenters you would like for future educational activities:

C. General comments about this conference:



